Hormone replacement therapy increases renal kallikrein excretion in healthy postmenopausal women

Life Sciences

Volumn 72, Issue 11, 2003, Pages 1279-1288

  Farag, Noha H ^a   Mahata, Manjula ^b   Ziegler, Michael G ^b   O'Connor, Daniel T ^b   Mills, Paul J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Blood pressure; Estrogen; Kallikrein; Medroxyprogesterone; Menopause

Indexed keywords

CREATININE; ESTRADIOL; KALLIKREIN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE URINE LEVEL; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HEALTH STATUS; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; NORMAL HUMAN; POSTMENOPAUSE; TIME; URINALYSIS; URINARY EXCRETION;

AGED; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; KALLIKREINS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; POTASSIUM;

EID: 0037473874     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02380-9     Document Type: Article

References (39)

1. Welty F.K. Women and cardiovascular risk. Am J Cardiol. 88(suppl):2001;48J-52J.
2. Grodstein F., Stampfer M.J., Manson J.E., Golditz G.A., Willett W.C., Rosner B., Speizer F.E., Hennekens C.H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
3. Saitta A., Altavilla D., Cucinotta D., Morabito N., Frisina N., Corrado F., D'Anna R., Lasco A., Squadrito G., Gaudio A., Cancellieri F., Arcoraci V., Squadrito F. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilatation in postmenopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology. 21(9):2001;1512-1519.
4. Lieberman E.H., Gerhard M.D., Uethata A., Walsh B.W., Selwyn A.P., Ganz P., Yeung A.C., Creager M.A. Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 121:1994;936-941.
5. Woods J.W. Oral contraceptives and hypertension. Hypertension. II(Suppl 2):1988;II11-II15.
6. The WHO Multicenter Trial of the vasopressor effects of combined oral contraceptives. I. Comparisons with IUD. Contraception. 40:1989;129-145.
7. Oral Contraception Study. Oral Contraceptives and Health. 1974;Pitman, New York.
8. Elias A.N., Meshkinpour H., Valenta L.J. Attenuation of hypertension by conjugated estrogens. Nephron. 30:1992;89-92.
9. Lip G.Y.H., Beevers M., Churchill D., Beevrs D.G. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertns. 8:1994;491-494.
10. Manwaring P., Morfis L., Diamond T., Howes L. Effects of hormone replacement therapy on ambulatory blood pressure and vascular responses in normotensive women. Blood Pressure. 9:2000;22-27.
11. Light K., Hinderliter A.L., West S.G., Grewen K.M., Steege J.F., Sherwood A., Girdler S. Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. Journal of Hypertension. 19(2):2001;269-278.
12. Abelous J.E., Bardier E. Les Substances hypotensives des Purine humaine normale. C.R. Soc. Biol. (Paris). 66:1909;511-512.
13. Elliot A.H., Nuzum F.R. Urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology. 18:1934;462-474.
14. Margolius H.S. Kallikreins and kinins: some unanswered questions about system characteristics and roles in human disease. Hypertension. 26:1995;221-229.
15. Chen L.M., Dhung P., Chao S., Chao L., Chao J. Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochem Biophs Acta. 1131:1992;145-151.
16. Madeddu P., Glorioso N., Maioli M., Demontis M.P., Varoni M.V., Anania V., Xiong W., Chai K., Chao J. Regulation of rat renal kallikrein expression by estrogen and progesterone. J Hypertens. 9(suppl 6):1991;S244-S245.
17. Murray S.R., Chao J., Lin F.K., Chao L. Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol. 15(suppl 6):1990;S7-S16.
18. Meyer P., Werner E., Polzin A. Kallikrein concentration in mixed saliva after contraceptive administration or postmenopausal hormone replacement. Laryngorhinootologie. 77(9):1998;521-524.
19. Barrett-Connor E. The menopause, hormone replacement and cardiovascular disease: The epidemiologic evidence. Maturitas. 23:1996;227-234.
20. Henderson B.E., Paganini-Hill A., Ross R.K. Decreased mortality in users of estrogen replacement therapy. Ann Intern Med. 151:1991;75-78.
21. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. JAMA. 280:1998;605-613.
22. Herrington D.M., Reboussin D.M., Brosniham K.B., Sharp P.C., Shumaker S.A., Snyder T.E., Furberg C.D., Kowalchuk G.J., Stuckey T.D., Rogers W.J., Givens D.H., Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 343:2000;522-529.
23. Angerer P., Stork S., Kothny W., Schmitt P., von Schacky C. Effect of oral postmenopausal estrogen replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol. 21:2001;262-268.
24. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 273:1995;199-208.
25. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results form the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333.
26. Hulka B.S., Kaufman D.G., Fowler W.C. Jr., Grimson R.C., Greenberg B.G. Predominance of early endometrial cancers after long term estrogen use. JAMA. 244:1980;2419-2422.
27. Jick H., Watkins R.V., Hunter J.R., Dinan B.J., Madsen S., Rothman K.J., Walker A.M. Replacement estrogens and endometrial cancer. N Engl J Med. 300(5):1979;218-222.
28. Amundsen E., Putter J., Friberger P., Knos M., Larstraten M., Cleason G. Methods for determination of glandular kallikrein by means of a chromogenic tripeptide substrate. Advances in Experimental Medicine and Biology. 120A:1979;83-94 Fuji S., Moriya H., Suzuki T. Kinins II, Biochemistry, Pathophysiology, and Clinical Aspects. 1979;Plenum Press, New York.
29. Song C.K., Martinez J.A., Kailasam M.T., Dao T.T., Wong C.M., Parmer R.J., O'Connor D.T. Renal kallikrein excretion: Role of ethnicity, gender, environment, and genetic risk of hypertension. Journal of Human Hypertension. 14:2000;461-468.
30. Fang S., Abe K., Omata K., Yasujima M., Yoshinaga K. The effects of aging on urinary kallikreins and other vasoactive substances in essential hypertension. Adv Exp Med Biol. 247B:1989;139-144.
31. Weiner C.P., Lizasoain I., Baylis S.A., Knowles R.G., Charles I.G., Moncada S. Induction of calcium dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci. U.S.A. 91:1994;5212-5521.
32. Reis S.E., Gloth S.T., Blumental R.S., Resar J.R., Zacur H.A., Gerstenblith G., Brinker J.A. Ethinyl estadiol acutely attenuates abnormal coronary responses to acetycholine in postmenopausal women. Circulation. 89:1994;52-60.
33. Parratt J.R. Protection of the heart by ischemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sci. 15:1994;19-25.
34. Linz W., Wiemer G., Gohlke P., Unger T., Scholkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47:1995;25-49.
35. Hunt K., Vessey M. Long-term effects of postmenopausal hormone therapy. British Journal of Hospital Medicine. 38:1987;450-460.
36. Meneton P., Bloch-Faure M., Hagege A.A., Ruetten H., Huan W., Bergaya S., Ceiler D., Gehring D., Martins I., Salmon G., Boulanger C.M., Nussberger J., Crozatier B., Gasc J.M., Heudes D., Bruneval P., Doetschman T., Menard J., Alhenc F., Gelas F. Cardiovascular abnormalities with normal blood pressure in tissuekallikrein-deficient mice. PNAS. 98(5):2001;2634-2639.
37. Kailasam M.T., Martinez J.A., Cervenka J.H., Yen S.S.C., O'Connor D.T., Parmer R.J. Racial differences in renal kallikrein excretion: Effect of the ovulatory cycle. Kidney International. 54:1998;1652-1658.
38. Khaw K.T. Women. Hormones and blood pressure. Canadian Journal of Cardiology. 12(Suppl D):1996;9D-12D.
39. August P., Oparil S. Hypertension in women. Journal of Clinical Endocrinology and Metabolism. 84(6):1999;1862-1866.